Pharmaceuticals

Global Antibody Drug Conjugates Contract Manufacturing Market Size Projected to Reach $15.37 Billion During the Forecast Period

November 10, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

By How Much Is The Antibody Drug Conjugates Contract Manufacturing Market Expected To Expand Between 2025 And 2029?

The antibody drug conjugates contract manufacturing market size has experienced rapid expansion in recent years. It is anticipated to increase from $9.57 billion in 2024 to $10.55 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 10.2%. The growth observed in previous periods stems from factors such as the increasing prevalence of cancer, a growing demand for targeted therapies, ongoing improvements in antibody drug conjugates, rising investment in research and development, regulatory approvals for new ADCs, and the broader expansion of pharmaceutical companies.

The market for contract manufacturing of antibody drug conjugates is projected to experience robust expansion in the coming years. This market is anticipated to reach $15.37 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 9.9%. The expansion during the forecast period is attributable to factors such as the expected rise of personalized medicine, broader applications extending beyond oncology, an increase in partnerships between biotechnology and pharmaceutical firms, the growing use of ADCs in clinical trials, and a heightened focus on economical manufacturing approaches. Key trends for this period encompass improvements in biomarker identification, progress in biotechnology, the increasing implementation of next-generation ADC technologies, developments in linker and payload technologies, and the incorporation of artificial intelligence for drug creation.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=18954&type=smp

Which Drivers Are Impacting The Antibody Drug Conjugates Contract Manufacturing Market?

The expanding biopharmaceutical sector is anticipated to stimulate the advancement of the antibody-drug conjugates contract manufacturing market moving forward. This industry primarily focuses on creating, producing, and marketing medications derived from biological sources, employing biotechnology and molecular biology to develop innovative therapies and treatments. The biopharmaceutical industry’s growth is driven by rapid progress in biotechnology, increasing demand for personalized medicine, and greater investment in research and development for cutting-edge therapies. Antibody-drug conjugates (ADCs) contract manufacturing aids the biopharmaceutical industry by providing specialized production services that facilitate the development and commercialization of these advanced treatments. This enables biopharmaceutical companies to efficiently scale up production and maintain high-quality standards while concentrating on their core research and development activities. For instance, in May 2024, data from the Department of Health and Social Care, a UK-based government department, indicated that the core biopharmaceutical sector generated £46.7 billion ($59.32 billion) in revenue in 2021/22, making up 43% of the entire life sciences industry. Thus, the increasing biopharmaceutical industry is a primary catalyst for the growth of the antibody-drug conjugates contract manufacturing market.

What Are The Major Segments Identified In The Antibody Drug Conjugates Contract Manufacturing Market?

The antibody drug conjugates contract manufacturing market covered in this report is segmented –

1) By Type: Immunoglobulin G1(Igg1), Immunoglobulin G4(Igg4)

2) By Linker: Cleavable Linker, Non-Cleavable Linker

3) By Condition: Myeloma, Lymphoma, Breast Cancer, Other Conditions

4) By Phase: Clinical, Commercial

What Are The Latest Industry Trends Transforming The Antibody Drug Conjugates Contract Manufacturing Market?

Companies operating in the antibody-drug conjugates contract manufacturing market are concentrating on developing novel products, such as single-use reactors, to enhance manufacturing flexibility, minimize contamination risks, and optimize the production process, thereby improving the efficiency and scalability of ADC production. Single-use reactors are transforming the field of antibody-drug conjugates (ADCs) contract manufacturing by offering a versatile, efficient, and contamination-free solution for producing these intricate biologics. For instance, in September 2024, MilliporeSigma, a US-based life science company, introduced the Mobius ADC Reactor, a single-use reactor. The Mobius ADC Reactor is specifically engineered for the efficient manufacturing of antibody-drug conjugates (ADCs). This reactor integrates advanced mixing and control technologies to simplify conjugation, improve scalability, and ensure greater consistency. This innovative reactor facilitates higher yields and better quality control in ADC production, addressing the growing need for targeted cancer therapies with enhanced safety and efficacy.

Which Key Players Are Driving Competition In The Antibody Drug Conjugates Contract Manufacturing Market?

Major companies operating in the antibody drug conjugates contract manufacturing market are AbbVie Inc., Eli Lilly and Company, Gilead Sciences Inc., Merck KGaA, Boehringer Ingelheim, Recipharm AB, Sigma-Aldrich, Sartorius AG, Curia, Lonza Group AG, Catalent Inc., KBI Biopharma, Alcami Corporation, Formosa Laboratories, BioVectra Inc., Axplora, Abzena PLC, ImmunoGen Inc., EirGenix Inc., Avid Bioservices Inc., Mersana Therapeutics, Cerbios-Pharma SA, Creative Biolabs, Aurigene Pharmaceutical Services Ltd., Sterling Pharma Solutions

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/antibody-drug-conjugates-contract-manufacturing-global-market-report

Which Region Currently Holds The Largest Share Of The Antibody Drug Conjugates Contract Manufacturing Market?

North America was the largest region in the antibody drug conjugates contract manufacturing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the antibody drug conjugates contract manufacturing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Antibody Drug Conjugates Contract Manufacturing Market Report:

https://www.thebusinessresearchcompany.com/customise?id=18954&type=smp

Browse Through More Reports Similar to the Global Antibody Drug Conjugates Contract Manufacturing Market 2025, By The Business Research Company

Antibody Drug Conjugates Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/antibody-drug-conjugates-global-market-report

Antibody Contract Manufacturing Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/antibody-contract-manufacturing-global-market-report

Next Generation Antibody Therapeutics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/next-generation-antibody-therapeutics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795